103 completed, 17 unknown, 9 recruiting, 5 active not recruiting. 52 Phase 1, 36 Phase 4, 23 Phase 3, 13 Phase 2, 10 Not applicable.
Follow Canagliflozin: new trials by email Literature Review of Canagliflozin trials Research Report on Canagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer LNG-IUS: levonorgestrel intrauterine system, Metformin, Canagliflozin - Endometrioid Endometrial Cancer, Atypical Endometrial Hyperplasia | Phase 2 | Not yet recruiting | Wang Yingmei | 102 | 2027-01-01 | 2026-10-22 |
| Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer Canagliflozin - Solid Tumor, SGLT 2 Inhibitors | Phase 1 | Recruiting | West China Hospital | 15 | 2026-09-10 | 2026-09-09 |
| CANagliflozin In DIALysis Patients Invokana 300 mg and 100 mg tablet - Dialysis, Chronic Kidney Disease (Stages 4 and 5) | Phase 4 | Not yet recruiting | University Medical Center Groningen | 10 | 2026-06-01 | 2026-05-06 |
| SGLT2 Inhibitor Utilization Re-perfusion Therapy Canagliflozin 100mg - Acute Ischemic Stroke From Large Vessel Occlusion | Phase 4 | Not yet recruiting | Taichung Veterans General Hospital | 150 | 2026-04-13 | 2026-04-03 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis Canagliflozin 300 MG - ESRD, CKD (Chronic Kidney Disease) Stage 5D | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 30 | 2026-02-01 | 2026-03-16 |
| Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer Canagliflozin - Colorectal Cancer, SGLT-2 Inhibitor | Phase 1 | Recruiting | West China Hospital | 15 | 2025-07-31 | 2025-07-22 |
| Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2 | Phase 4 | Completed | Fundación para la Investigación del Hospital Clínico de Valencia | 92 | 2025-05-26 | 2026-09-04 |
| Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists SGLT-2 inhibitor, GLP1-RA - Type 2 Diabetes (T2DM) | Phase 4 | Active not recruiting | MaryAnn Banerji | 60 | 2024-12-21 | 2026-01-08 |
| The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin - Acute Kidney Injury | Phase 2 | Recruiting | National Taiwan University Hospital | 264 | 2024-11-21 | 2026-01-02 |
| Canagliflozin Targeting Vascular Inflammation Canagliflozin, Placebo - Diabetes Type 2, Coronary Artery Disease | Phase 2 / Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 24 | 2024-11-15 | 2026-05-06 |
| Canagliflozin in Advanced Renal Disease With MRI Endpoints Canagliflozin 300Mg Tab, Placebo - ESRD, CKD Stage 4, CKD Stage 5 | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 92 | 2024-05-01 | 2025-12-08 |
| Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome Canagliflozin 100mg Tab, Metformin Hydrochloride - Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease | Phase 4 | Unknown | Ping Li,MD | 50 | 2024-03-31 | 2024-02-13 |
| The Efficacy and Tolerability of Canagliflozin in Healthy Individual Invokana Pill - Healthy Aging | Phase 4 | Completed | AgelessRx | 30 | 2024-02-12 | 2024-07-19 |
| Mechanism of SGLT2 Inhibition in the Kidney SGLT2 inhibitor - Type 2 Diabetes, Diabetic Kidney Disease | Phase 4 | Recruiting | University of Michigan | 20 | 2024-01-01 | 2026-06-11 |
| Canagliflozin With Gemcitabine in Pancreatic Carcinoma Canagliflozin and Gemcitabine, Gemcitabine - Pancreatic Cancer | Not applicable | Not yet recruiting | Zhang Xiaofeng,MD | 20 | 2023-10-01 | 2023-06-15 |
| Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide - Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Recruiting | Cardenal Herrera University | 250 | 2023-09-15 | 2025-12-30 | |
| Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor - Glomerulonephritis, Immunoglobulin A Nephropathy | Phase 4 | Recruiting | Fondazione Schena | 878 | 2023-05-01 | 2025-04-02 |
| Safety and Efficacy of Canagliflozin in Advanced CKD Invokana 300 mg and 100 mg tablet - ESRD, CKD Stage 4 | Phase 4 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 34 | 2022-11-24 | 2026-07-13 |
| Renal Mechanism of SGLT2 Inhibition canagliflozin, Aminohippurate Sodium Inj 20% - Type 2 Diabetes, Diabetic Kidney Disease | Phase 2 | Active not recruiting | University of Colorado, Denver | 45 | 2022-10-10 | 2026-06-02 |
Showing 20 of 144. Sign in to see all of them.
Diabetes Mellitus, Type 2 (67) · Diabetes Mellitus (15) · Obesity (8) · Insulin Resistance (7) · Renal Insufficiency, Chronic (7) · Diabetic Nephropathies (4) · Kidney Failure, Chronic (4) · Overweight (4) · Albuminuria (3) · Cardiovascular Diseases (3) · Hypertension (3) · Renal Insufficiency (3) · Body Weight Changes (2) · Breast Neoplasms (2) · Coronary Artery Disease (2)
Janssen Research & Development, LLC (38) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (30) · Tanabe Pharma Corporation (7) · Brigham and Women's Hospital (3) · McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · First Affiliated Hospital Xi'an Jiaotong University (2) · Janssen-Cilag International NV (2) · Johnson & Johnson Private Limited (2) · The University of Texas Health Science Center at San Antonio (2) · University of Maryland, Baltimore (2) · West China Hospital (2) · AgelessRx (1) · Alexandria University (1) · AstraZeneca (1) · Baylor Research Institute (1)
United States (74) · Canada (17) · China (16) · Mexico (16) · India (15) · Germany (14) · Spain (13) · Malaysia (11) · Poland (11) · Puerto Rico (11) · Russia (11) · United Kingdom (10) · Belgium (9) · Brazil (9) · France (9)
Kazuoki Kondo, MD (5) · Simeon I Taylor, MD, PhD (2) · Takashi Kadowaki, MD (2) · Thomas Mavrakanas, MD (2) · Ahmed F El-Yazbi, PhD (1) · Albert Yu, MD (1) · Amr El-Feky, MD (1) · Ana Checa-Ros, MD, PhD (1)
PMID 26580237, PMID 24517339, PMID 24786834, PMID 27977934, PMID 38770818, PMID 26121561, PMID 26579834, PMID 27600862, PMID 28241822, PMID 24742013, PMID 24918789, PMID 25329038, PMID 25813214, PMID 26373629, PMID 28197834, PMID 28327140, PMID 29313267, PMID 24585202, PMID 25345427, PMID 27140803, PMID 28605608, PMID 33826709, PMID 35938182, PMID 37120538, PMID 37345834, PMID 37671609, PMID 38240199, PMID 38807510, PMID 38932575, PMID 40105285, PMID 40239057, PMID 41198855, PMID 25659911, PMID 25795432, PMID 27002421, PMID 27136908, PMID 27391951, PMID 29133604, PMID 29526832, PMID 29693360, PMID 29937267, PMID 29941478, PMID 30591006, PMID 30882240, PMID 30990260, PMID 31399845, PMID 32691499, PMID 32694216, PMID 32971190, PMID 33595905
2025 (3), 2009 (2), 2015 (2), 2016 (2), 1OT2HL156812-01 (1), K12DK094714 (1), R01DK118942 (1), R21DK105401 (1)